niacin and Coronary Disease studies

Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.

Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.

Research Excerpts

Excerpt	Relevance	Reference
" In our study, patients were randomized, on average, 6 days after an acute myocardial infarction and/or percutaneous transluminal coronary angioplasty secondary to unstable angina, to pravastatin (combined, when necessary, with cholestyramine and/or nicotinic acid) to achieve low-density lipoprotein cholesterol levels of < or =130 mg/dl (group A, n = 70)."	9.09	Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). ( Agrawal, R; Arntz, HR; Fischer, F; Schnitzer, L; Schultheiss, HP; Stern, R; Wunderlich, W, 2000)
"Simvastatin plus niacin provides marked clinical and angiographically measurable benefits in patients with coronary disease and low HDL levels."	9.09	Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. ( Alaupovic, P; Albers, JJ; Bolson, EL; Brown, BG; Chait, A; Cheung, MC; Dowdy, AA; Fisher, LD; Frohlich, J; Marino, EK; Morse, JS; Zhao, XQ, 2001)
"Niacin was the first drug demonstrating lowered cholesterol prevents coronary heart disease (CHD) events, with two clinical CHD outcome studies establishing a cardioprotective niacin regimen: 1 g thrice daily with meals."	8.93	Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens. ( Dunbar, RL; Goel, H, 2016)
"Niacin is the most effective lipid-modifying agent for raising high-density lipoprotein cholesterol levels, but it also causes cutaneous vasodilation with flushing."	8.86	A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. ( Jacobson, TA, 2010)
"To review the pathophysiology and clinical relevance for using niacin to treat the metabolic syndrome."	8.82	The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin. ( Ito, MK, 2004)
"We conducted a case-control study nested in the New York University Women's Health Study to evaluate the association between circulating taurine levels and risk of coronary heart disease (CHD)."	7.79	Serum taurine and risk of coronary heart disease: a prospective, nested case-control study. ( Chen, Y; Costa, M; Koenig, KL; Pearte, C; Wójcik, OP; Zeleniuch-Jacquotte, A, 2013)
"The most common challenge during niacin treatment is flushing, although it typically decreases with ongoing use and can be ameliorated by pretreatment with aspirin and counseling by the prescriber."	6.48	Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review. ( McKenney, JM, 2012)
"Thus, the long-term treatment of dyslipidemias with these two agents may help to modify risk and reduce cardiovascular morbidity and mortality in these patients over and above benefits achieved by lowering blood pressure."	6.43	Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol. ( Chrysant, SG; Ibrahim, M, 2006)
"Patients with hypertriglyceridemia have been shown to respond well to dietary control and to the use of lipid lowering drugs such as 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA) reductase inhibitors (known as statins), fibrates and nicotinic acids."	6.41	Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. ( Breuer, HW, 2001)
"Extended-release niacin/laropiprant represents an effective therapeutic option for the treatment of dyslipidemia across a range of patient types."	5.15	Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. ( Bays, H; Dong, Q; Maccubbin, D; McCrary Sisk, C; Shah, A, 2011)
"Patients with coronary heart disease (CHD) or CHD equivalent with low-density lipoprotein cholesterol <100 mg/dl and high-density lipoprotein cholesterol <50 mg/dl for men or 55 mg/dl for women while receiving stable statin treatment were randomly assigned to ezetimibe (10 mg/day) or extended-release niacin (target dose, 2,000 mg/day)."	5.14	The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. ( Devine, PJ; Griffen, L; Miller, M; Stanek, EJ; Taylor, AJ; Turco, M; Villines, TC; Weissman, NJ, 2010)
"To evaluate the efficacy and safety of extended-release niacin (niacin ER) either alone or in combination with atorvastatin for the lipid profile modification in the patients with coronary heart disease (CHD) and its equivalents."	5.12	[Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification]. ( Duan, J; Li, XP; Tan, MY; Xu, ZM; Zhang, DQ; Zhao, SP, 2006)
"The addition of extended-release niacin to statin therapy slowed the progression of atherosclerosis among individuals with known coronary heart disease and moderately low HDL-C."	5.11	Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. ( Grace, KA; Lee, HJ; Lee, JK; Sullenberger, LE; Taylor, AJ, 2004)
"Simvastatin plus niacin provides marked clinical and angiographically measurable benefits in patients with coronary disease and low HDL levels."	5.09	Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. ( Alaupovic, P; Albers, JJ; Bolson, EL; Brown, BG; Chait, A; Cheung, MC; Dowdy, AA; Fisher, LD; Frohlich, J; Marino, EK; Morse, JS; Zhao, XQ, 2001)
" In our study, patients were randomized, on average, 6 days after an acute myocardial infarction and/or percutaneous transluminal coronary angioplasty secondary to unstable angina, to pravastatin (combined, when necessary, with cholestyramine and/or nicotinic acid) to achieve low-density lipoprotein cholesterol levels of < or =130 mg/dl (group A, n = 70)."	5.09	Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). ( Agrawal, R; Arntz, HR; Fischer, F; Schnitzer, L; Schultheiss, HP; Stern, R; Wunderlich, W, 2000)
" Six hundred and twelve patients with postdiet LDL cholesterol (LDL-C) levels in the range of 190-230 mg/dl (or 160-230 mg/dl for those with coronary heart disease or two or more coronary risk factors) were randomized to a stepped-care regimen (initial treatment with niacin followed by other agents if needed) or to initial use of lovastatin, an HMG-CoA reductase inhibitor."	5.08	A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS). ( Benson, VV; Borok, GM; Dudl, RJ; Epstein, A; Epstein, RS; Heys, JF; Menzin, J; Oster, G; Quinn, V, 1995)
"Niacin was one of the treatments compared in the Coronary Drug Project, a placebo-controlled, multicenter trial of lipid-lowering drugs in the secondary prevention of coronary heart disease."	5.07	Coronary drug project: experience with niacin. Coronary Drug Project Research Group. ( Berge, KG; Canner, PL, 1991)
"Niacin (nicotinic acid) is a potent lipid-lowering agent that has been used for prevention of coronary heart disease."	5.01	Activation of HCAR2 by niacin: benefits beyond lipid lowering. ( Tuteja, S, 2019)
"Niacin was the first drug demonstrating lowered cholesterol prevents coronary heart disease (CHD) events, with two clinical CHD outcome studies establishing a cardioprotective niacin regimen: 1 g thrice daily with meals."	4.93	Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens. ( Dunbar, RL; Goel, H, 2016)
"Neither niacin, fibrates, nor CETP inhibitors, three highly effective agents for increasing high density lipoprotein levels, reduced all cause mortality, coronary heart disease mortality, myocardial infarction, or stroke in patients treated with statins."	4.90	Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. ( Francis, DP; Keene, D; Price, C; Shun-Shin, MJ, 2014)
"Niacin is the most effective lipid-modifying agent for raising high-density lipoprotein cholesterol levels, but it also causes cutaneous vasodilation with flushing."	4.86	A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. ( Jacobson, TA, 2010)
"Laropiprant is a highly selective prostaglandin D2 receptor 1 antagonist that mitigates niacin-induced flushing."	4.85	What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? ( Ballantyne, C; Bays, HE, 2009)
" As a result of new data, guidelines have begun to focus on non-HDL-cholesterol, HDL-cholesterol and triglycerides as treatment targets, with the end result being a recommendation for combination therapy, such as niacin plus statin for the treatment of dyslipidemia."	4.84	Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders. ( Kashyap, ML; Vo, AN, 2008)
"MEDLINE was searched for articles published from 1990 through 2006 using the terms hypertriglyceridemia, dyslipidemia, and coronary heart disease, with subheadings for risk, statins, niacin, fibrates, thiazolidinediones, and omega-3 fatty acids."	4.84	Hypertriglyceridemia and cardiovascular risk reduction. ( Jacobson, TA; Miller, M; Schaefer, EJ, 2007)
"To review the pathophysiology and clinical relevance for using niacin to treat the metabolic syndrome."	4.82	The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin. ( Ito, MK, 2004)
" Many of these patients, as well as persons at heightened risk for cardiovascular disease because of a range of heritable conditions (eg, familial hypercholesterolemia, familial combined hyperlipidemia), will undoubtedly require binary or ternary regimens involving statins in concert with niacin, fibric-acid derivatives, or bile acid resins."	4.81	Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century. ( Jacobson, TA, 2001)
"This study determined time trends between 2007 and 2011 for statin and nonstatin lipid-lowering therapy (niacin, fibrates, bile acid sequestrants, and ezetimibe) use among Medicare beneficiaries with coronary heart disease (CHD) in light of emerging clinical trial evidence."	3.81	Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011. ( Bittner, V; Deng, L; Farkouh, ME; Glasser, SP; Kent, ST; Muntner, P; Rosenson, RS; Taylor, B, 2015)
"We conducted a case-control study nested in the New York University Women's Health Study to evaluate the association between circulating taurine levels and risk of coronary heart disease (CHD)."	3.79	Serum taurine and risk of coronary heart disease: a prospective, nested case-control study. ( Chen, Y; Costa, M; Koenig, KL; Pearte, C; Wójcik, OP; Zeleniuch-Jacquotte, A, 2013)
" The statins can be used alone, or in combination with a bile acid sequestrant, ezetimibe, or niacin in patients with mixed dyslipidemias."	3.72	Achieving cholesterol goals. Current and future drug therapies. ( Jones, PH, 2003)
"Results of recent clinical trials on secondary prevention of ischemic heart disease indicate that judicious, long-term administration of adrenergic beta blockers and platelet-active drugs such as aspirin and Persantine (dipyridamole) would seem to yield protection against mortality associated with acute myocardial infarction, including sudden death."	3.67	Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases. ( Borhani, NO, 1985)
"placebo on the incidence of new onset type 2 diabetes mellitus (T2DM) and cardiovascular event rates in patients with normal and impaired fasting glucose (IFG)."	2.78	Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. ( Canner, PL; Maccubbin, D; Sazonov, V; Sisk, CM, 2013)
"Forty-nine middle-aged men with dyslipidemia and established CAD who were undergoing intensive lipid-lowering therapy were studied."	2.70	Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. ( Brown, BG; Brunzell, JD; Deeb, SS; Hokanson, JE; Zambon, A, 2001)
"Niacin treatment (alone) was compared with etofibrate and niacin combination to treat patients with high-density lipoprotein <35 mg/dl and without hypertriglyceridemia."	2.69	Effect of niacin and etofibrate association on subjects with coronary artery disease and serum high-density lipoprotein cholesterol <35 mg/dl. ( Caramelli, B; Mansur, AP; Ramires, JA; Serrano, CV; Spósito, AC, 1999)
"The hypolipidemic effects of induracin, a new long-acting nicotinic acid dosage form based on the waxy matrix, and its tolerance were studied in 31 patients with Types IIa and IIb hyperlipoproteinemias in a 6-month blind crossover study."	2.67	[The use of Enduracin--a prolonged-action form of nicotinic acid--in correcting atherogenic dyslipidemias]. ( Akhmedzhanov, NM; Aronov, DM; Kiseleva, NG; Kiseleva, NS; Oganov, RG; Olfer'ev, AM; Perova, NV, 1993)
"The most common challenge during niacin treatment is flushing, although it typically decreases with ongoing use and can be ameliorated by pretreatment with aspirin and counseling by the prescriber."	2.48	Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review. ( McKenney, JM, 2012)
"The niacin model was moderately different from the statin model (K = 7."	2.45	Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. ( Jacobson, TA; Robinson, JG; Smith, BJ; Wang, S, 2009)
"Patients with type 2 diabetes have a marked increase in the risk of premature coronary heart disease (CHD)."	2.44	Dyslipidaemia in diabetic patients: time for a rethink. ( Shepherd, J, 2007)
"Coronary heart disease is a major cause of mortality in women in Western industrialised countries, particularly after the age of 50 years, coinciding with the onset of the menopause and potentially adverse metabolic changes that occur during the transitional peri-menopausal and post-menopausal periods."	2.44	HDL-C in post-menopausal women: An important therapeutic target. ( Collins, P, 2008)
"Thus, the long-term treatment of dyslipidemias with these two agents may help to modify risk and reduce cardiovascular morbidity and mortality in these patients over and above benefits achieved by lowering blood pressure."	2.43	Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol. ( Chrysant, SG; Ibrahim, M, 2006)
"Niacin has a more potent effect on HDL-C levels, whereas data on cardiovascular event rate reduction are limited."	2.43	Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. ( Birjmohun, RS; Hutten, BA; Kastelein, JJ; Stroes, ES, 2005)
"Niacin has multifarious lipoprotein and anti-atherothrombosis effects that improve endothelial function, reduce inflammation, increase plaque stability, and diminish thrombosis."	2.42	Antiatherothrombotic effects of nicotinic acid. ( Rosenson, RS, 2003)
"Niacin has been widely used as a pharmacologic agent to regulate abnormalities in plasma lipid and lipoprotein metabolism and in the treatment of atherosclerotic cardiovascular disease."	2.42	Niacin and cholesterol: role in cardiovascular disease (review). ( Ganji, SH; Kamanna, VS; Kashyap, ML, 2003)
"However, many patients with dyslipidemia who have or are at risk for CHD do not reach target LDL-C goals."	2.42	Therapy to reduce risk of coronary heart disease. ( Rader, DJ, 2003)
"Niacin has been known to be an effective treatment of dyslipidemia for almost half a century."	2.42	Niacin as a component of combination therapy for dyslipidemia. ( Miller, M, 2003)
"Patients with hypertriglyceridemia have been shown to respond well to dietary control and to the use of lipid lowering drugs such as 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA) reductase inhibitors (known as statins), fibrates and nicotinic acids."	2.41	Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. ( Breuer, HW, 2001)
" These issues of possible harm or lack of benefit from long-term use of lipid-lowering therapy, and cost effectiveness, are also pertinent in the pediatric setting."	2.41	Should pediatric patients with hyperlipidemia receive drug therapy? ( Bhatnagar, D, 2002)
"There is clear evidence that treating hypercholesterolemia reduces cardiovascular risk in women, as well as in men."	2.41	Management of hypercholesterolaemia in postmenopausal women. ( Davidson, MH; Ingram, KA; Karp, SK; Maki, KC, 2002)
"Advances in treatment of elevated cholesterol levels and recent documentation of efficacy and safety in clinical trials justify expanded use of cholesterol-lowering therapy in clinical practice."	2.40	Cholesterol management in patients with heart disease. Emphasizing secondary prevention to increase longevity. ( Grundy, SM, 1997)
"Treatment of dyslipidemia to prevent CHD depends on the pattern and severity of dyslipidemia, the presence of overt CHD, and the patient's response to diet."	2.40	Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease. ( Borgia, MC; Medici, F, 1998)
"Several forms of dyslipidemia are associated with premature coronary artery disease (CAD) and other vascular disease."	2.39	Hyperlipidemia: perspectives in diagnosis and treatment. ( Gotto, AM; Yeshurun, D, 1995)
"Hypertriglyceridemia is a well-known risk factor for pancreatitis."	2.38	The triglyceride connection in atherosclerosis. ( Geurian, K; Pinson, JB; Weart, CW, 1992)
"Ezetimibe is a lipid lowering medication that is able to inhibit dietary cholesterol."	1.36	Ezetimibe and recent clinical trials: a look on the bright side. ( Ahmed, MH, 2010)
"Likewise, the metabolic syndrome is a secondary target of treatment."	1.32	CHD risk equivalents and the metabolic syndrome. Trial evidence supports aggressive management. ( Thompson, PD, 2003)
"0 were treated with niacin, commencing at low dosages (100 to 250 mg twice daily) and gradually increasing the dosage over 4 to 8 weeks to 1,000 mg twice daily."	1.28	Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. ( Alderman, JD; Grossman, W; Monrad, ES; Pasternak, RC; Sacks, FM; Smith, HS, 1989)

Research

Studies (225)

Authors

Clinical Trials (21)

Trial Overview

Trial Outcomes

Coronary or Non-coronary Revascularisation

Timeframe	Studies, this research(%)	All Research%
pre-1990	51 (22.67)	18.7374
1990's	50 (22.22)	18.2507
2000's	95 (42.22)	29.6817
2010's	29 (12.89)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Tuteja, S	1
Parish, S	1
Hopewell, JC	1
Hill, MR	1
Marcovina, S	1
Valdes-Marquez, E	1
Haynes, R	1
Offer, A	1
Pedersen, TR	1
Baigent, C	1
Collins, R	1
Landray, M	1
Armitage, J	1
Sazonov, V	2
Maccubbin, D	2
Sisk, CM	1
Canner, PL	2
Kumar, S	1
Rai, H	1
Kapoor, A	1
Tewari, S	1
Sinha, N	1
Keene, D	1
Price, C	1
Shun-Shin, MJ	1
Francis, DP	1
Hourcade-Potelleret, F	1
Laporte, S	1
Lehnert, V	1
Delmar, P	1
Benghozi, R	1
Torriani, U	1
Koch, R	1
Mismetti, P	1
Bittner, V	1
Deng, L	1
Rosenson, RS	4
Taylor, B	1
Glasser, SP	1
Kent, ST	1
Farkouh, ME	1
Muntner, P	1
Dunbar, RL	1
Goel, H	1
Kamanna, VS	2
Vo, A	1
Kashyap, ML	4
Tovar, JM	1
Bazaldua, OV	1
Loffredo, A	1
Svilaas, A	1
Strandberg, T	1
Eriksson, M	1
Hildebrandt, P	1
Westheim, A	1
Belsey, J	1
de Lusignan, S	1
van Vlymen, J	1
Chan, T	1
Hague, N	1
Vo, AN	1
Robinson, JG	1
Wang, S	1
Smith, BJ	1
Jacobson, TA	4
Nair, AP	1
Darrow, B	1
Guthrie, RM	1
Jones, PH	2
Thompson, PD	1
Bays, HE	1
Ballantyne, C	1
Bitzur, R	1
Cohen, H	1
Kamari, Y	1
Shaish, A	1
Harats, D	1
Blumenthal, RS	1
Michos, ED	1
Taylor, AJ	3
Villines, TC	2
Stanek, EJ	2
Devine, PJ	2
Griffen, L	2
Miller, M	4
Weissman, NJ	2
Turco, M	2
Kastelein, JJ	5
Bots, ML	1
Kole, LA	1
Parhofer, K	1
Lindsay, AC	1
Halcox, JP	1
Duivenvoorden, R	1
Vergeer, M	1
Roman, MJ	1
Weiss, SH	1
Natarajan, P	1
Ray, KK	1
Cannon, CP	1
Ahmed, MH	1
Gupta, A	1
Guyomard, V	1
Zaman, MJ	1
Rehman, HU	1
Myint, PK	1
Bays, H	2
Shah, A	1
Dong, Q	1
McCrary Sisk, C	1
Dolgin, E	1
Virani, SS	1
Ballantyne, CM	1
Einecke, D	1
McKenney, JM	2
Wójcik, OP	1
Koenig, KL	1
Zeleniuch-Jacquotte, A	1
Pearte, C	1
Costa, M	1
Chen, Y	1
Dänschel, W	1
Steinhagen-Thiessen, E	1
Buffleben, C	1
Pittrow, D	1
Hildemann, SK	1
Pirillo, A	1
Norata, GD	1
Catapano, AL	1
Barter, P	1
Packard, C	1
Olsson, AG	1
Nagai, Y	1
Yanagi, K	1
Yamashita, S	1
Takemura, K	1
Matsuzawa, Y	1
McKenney, J	1
Duvall, WL	1
Blazing, MA	2
Saxena, S	1
Guyton, JR	3
Rader, DJ	2
Ganji, SH	1
Talbert, RL	1
Pieper, JA	1
Ito, MK	2
Davidson, MH	2
GOLDSBOROUGH, CE	1
POPA, Iu	1
DE RITIS, F	1
ASCIONE, A	1
MATANO, F	1
DOAK, PB	1
NICHOLSON, GI	1
NORTH, JD	1
GORODINS'KA, VIa	1
SIMON, IB	1
HEYDEN, S	1
KNUECHEL, F	1
LANGE, K	1
MAHL, M	1
JAROSCHEWSKI, AJ	1
SHAWORONKOWA, EK	1
DIVERSI, R	1
NESTEL, PJ	1
FERNANDEZBLANCO, E	1
DEFERNANDEZBLANCO, JF	1
AGUSTINARZENO, J	1
FAZEKAS, JF	1
ALMAN, RW	1
TICKTIN, HE	1
EHRMANTRAUT, WR	1
SAVARESE, CJ	1
BLANKENHORN, DH	2
CHIN, HP	1
ILIESCU, M	1
DOMOCOS, G	1
IACOBINI, P	1
CONSTANTINESCU, S	1
ILIESCU, CC	1
IAROSHEVSKII, AIa	1
ZHAVORONKOVA, EK	1
MENEGHINI, P	1
AVANZI, G	1
BUEDINGEN, F	1
MOELLER, HC	1
FEUSER, J	1
FEARNLEY, GR	1
WENNERBY, S	1
GHIA, G	1
MEREU, D	1
MACCARINI, PA	1
FREZZA, S	1
KEDRA, M	1
MARKIEWICZ, M	1
MITURZYNSKA, H	1
LIOTTA, S	1
STERN, ML	1
BODE, G	1
HUNTER, JD	2
SCOPPOLA, L	1
GANDINI, L	1
Ng, DS	1
Schuster, H	1
Wild, S	1
Byrne, CD	1
Chapman, MJ	2
Assmann, G	2
Fruchart, JC	1
Shepherd, J	2
Sirtori, C	1
Spratt, KA	1
Denke, MA	2
Sullenberger, LE	1
Lee, HJ	1
Lee, JK	1
Grace, KA	1
Grundy, SM	5
Charlotte, N	1
Sani, M	1
Birjmohun, RS	1
Hutten, BA	1
Stroes, ES	1
Whitney, EJ	2
Krasuski, RA	1
Personius, BE	2
Michalek, JE	1
Maranian, AM	1
Kolasa, MW	1
Monick, E	1
Brown, BG	9
Gotto, AM	4
Creavin, T	1
Rassman, J	1
Gupta, S	1
Wieneke, H	1
Schmermund, A	1
Erbel, R	1
Carlson, LA	1
Reasner, CA	1
Young, IS	1
Nicholls, DP	1
Chrysant, SG	1
Ibrahim, M	1
Li, XP	1
Duan, J	1
Zhao, SP	1
Tan, MY	1
Xu, ZM	1
Zhang, DQ	1
Veryard, C	1
Pal, M	1
Pillarisetti, S	1
Rana, JS	1
Nieuwdorp, M	1
Jukema, JW	1
Schaefer, EJ	2
Collins, P	1
Roze, S	1
Ferrières, J	1
Bruckert, E	1
Van Ganse, E	1
Liens, D	1
Renaudin, C	1
Abdel-Maksoud, M	1
Gutkin, SW	1
Hokanson, JE	2
Stamler, J	1
Lamping, KA	1
Menahan, LA	1
Gross, GJ	2
Denisiuk, VI	1
Kuo, PT	2
Kostis, JB	1
Moreyra, AE	1
Lapuerta, P	1
Azen, SP	1
LaBree, L	1
Ginsberg, HN	2
Hillger, L	2
Zhao, XQ	7
Poulin, D	2
Albers, JJ	7
Yeshurun, D	1
Oster, G	1
Borok, GM	1
Menzin, J	1
Heys, JF	1
Epstein, RS	1
Quinn, V	1
Benson, VV	1
Dudl, RJ	1
Epstein, A	1
Kiseleva, NG	2
Probstfield, JL	1
Hunninghake, DB	3
Stewart, BF	1
Hillger, LA	1
Sniderman, AD	1
Dowdy, A	2
Fisher, LD	4
Paterson, RW	1
Paat, JJ	1
Steele, GH	1
Hathaway, SC	1
Wong, JG	1
Oganov, RG	1
Aronov, DM	1
Akhmedzhanov, NM	1
Olfer'ev, AM	1
Kiseleva, NS	1
Perova, NV	1
Rodriguez, CR	1
Seman, LJ	1
Ordovas, JM	1
Jenner, J	1
Genest, MS	1
Wilson, PW	1
Hodis, HN	1
Sacco, D	1
Bisson, B	1
Fisher, L	1
Cortner, JA	1
Coates, PM	1
Liacouras, CA	1
Jarvik, GP	1
Schectman, G	1
Hiatt, J	1
Holme, I	1
Schiel, R	1
Bambauer, R	1
Müller, UA	1
Parsons, WB	1
Avery, BR	1
Andrews, TC	1
Green, G	1
Kalenian, R	1
O'Keefe, JH	1
Harris, WS	1
Zambon, A	2
Rocha, A	1
Maher, VM	1
Davis, JW	1
Brunzell, JD	2
Borgia, MC	1
Medici, F	1
Chait, A	3
Frohlich, J	2
Cheung, M	1
Heise, N	1
DeAngelis, D	1
Albers, J	1
Spósito, AC	1
Caramelli, B	1
Serrano, CV	1
Mansur, AP	1
Ramires, JA	1
Gordon, BR	1
Saal, SD	1
Arntz, HR	2
Wunderlich, W	2
Schnitzer, L	2
Stern, R	2
Fischer, F	2
Agrawal, R	2
Linderer, T	1
Schultheiss, HP	2
Otto, C	1
Schwandt, P	1
Hagar, J	1
Knopp, RH	2
Nash, DT	1
Nash, SD	1
Lavie, CJ	3
Isles, CG	1
Paterson, JR	1
Boden, WE	1
Pearson, TA	1
von Eckardstein, A	1
Bowen, PH	1
Coughlan, BJ	1
Sorrentino, MJ	1
Safeer, RS	1
Cornell, MO	1
Deeb, SS	1
Ogaki, S	1
Matsushima, T	1
Legato, MJ	1
Sprecher, DL	1
Smith, SC	1
Milani, RV	2
Parsons , WB	1
Breuer, HW	1
Cheung, MC	2
Szapary, PO	1
Netke, S	1
Ivanov, V	1
Roomi, W	1
Niedzwiecki, A	1
Rath, M	1
Morse, JS	1
Dowdy, AA	1
Marino, EK	1
Bolson, EL	1
Alaupovic, P	1
Freedman, JE	1
Sacks, FM	2
Wink, J	1
Giacoppe, G	1
King, J	1
Stein, EA	1
Bhatnagar, D	1
Klungel, OH	1
Heckbert, SR	1
de Boer, A	1
Leufkens, HG	1
Sullivan, SD	1
Fishman, PA	1
Veenstra, DL	1
Psaty, BM	1
Maki, KC	1
Karp, SK	1
Ingram, KA	1
Geurian, K	1
Pinson, JB	1
Weart, CW	1
Mailander, L	1
Superko, HR	1
Krauss, RM	1
Drood, JM	1
Zimetbaum, PJ	1
Frishman, WH	1
Pasternak, RC	2
Kolman, BS	1
Khamidov, NKh	1
Dodobaeva, MS	1
Berge, KG	1
Chernomorets, NN	1
Kotlubeĭ, GV	1
Vatutin, NT	1
Zhivotovskaia, IA	2
Gnilitskaia, VB	2
Alifanova, RE	2
Lobach, EIa	1
Mal'tseva, NV	2
Mitrofanov, AN	1
Brown, G	1
Schaefer, SM	1
Lin, JT	1
Kaplan, C	1
Bisson, BD	1
Fitzpatrick, VF	1
Dodge, HT	1
Miller, NE	1
van Bilsen, M	1
van der Vusse, GJ	1
Willemsen, PH	1
Coumans, WA	1
Roemen, TH	1
Reneman, RS	1
Pieper, GM	1
Warltier, DC	1
Kats, GL	1
Alderman, JD	1
Smith, HS	1
Monrad, ES	1
Grossman, W	1
Borhani, NO	1
Lueg, MC	1
Anding, RH	1
Naito, HK	1
Rudzite, V	1
Jirgensons, J	1
Jurika, E	1
Sileniece, G	1
Zirne, R	1
Jirgensone, S	1
Scott, LW	1
Hoeg, JM	1
Starzl, TE	1
Brewer, HB	1
Noseda, G	1
Cohen, M	1
TERRIS, M	1
Walker, AR	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant[NCT00461630]	Phase 3	25,673 participants (Actual)	Interventional	2007-01-31	Completed
Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940]	Phase 3	120 participants (Actual)	Interventional	2018-05-28	Active, not recruiting
Hypertension Management and Outcomes in a Family Practice Setting[NCT03579108]		200 participants (Anticipated)	Observational	2018-02-24	Recruiting
Post-prandial Effects of Extra Virgin Olive Oil on Endothelial Function in Adults at Risk for Type 2 Diabetes: A Randomized Crossover Controlled Trial[NCT04025281]		20 participants (Actual)	Interventional	2019-07-09	Completed
The Impact of Consumption of Eggs in the Context of Plant-Based Diets on[NCT04316429]		35 participants (Actual)	Interventional	2020-06-09	Completed
ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)[NCT00397657]	Phase 4	400 participants (Anticipated)	Interventional	2006-11-30	Terminated (stopped due to Independent steering committee has stopped the trial based on results of a prespecified, blinded interim analysis. It was not stopped due to safety concerns.)
ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART[NCT01683656]	Phase 4	4 participants (Actual)	Interventional	2012-08-31	Terminated (stopped due to Withdrawal of IMP from the market. Data on risk-benefit ratio pending.)
"A Multicenter, Randomized, Double-Blind, Factorial Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Coadministered MK0524B Tablets in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia"[NCT00269217]	Phase 3	1,400 participants (Actual)	Interventional	2006-01-31	Completed
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia[NCT00269204]	Phase 3	1,620 participants (Actual)	Interventional	2005-12-31	Completed
A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of Extended-release (ER) Niacin/Laropiprant in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia.[NCT00479388]	Phase 3	1,216 participants (Actual)	Interventional	2007-07-31	Completed
A Multicenter, Randomized, Double-Blind, Placebo Controlled 36 Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients With Type 2 Diabetes[NCT00485758]	Phase 3	796 participants (Actual)	Interventional	2007-07-31	Completed
[NCT00006295]		370 participants (Anticipated)	Observational	2000-08-31	Completed
Randomized, Double-blind, Placebo-controlled Trial of Niaspan® in Patients With Overt Diabetic Nephropathy and Moderate Renal Impairment[NCT00108485]	Phase 3	9 participants (Actual)	Interventional	2005-04-30	Terminated (stopped due to Unable to recruit sufficient study subjects)
Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol[NCT01131299]	Phase 2	103 participants (Actual)	Interventional	2010-03-31	Completed
Familial Atherosclerosis Treatment Study[NCT00000512]	Phase 3	146 participants (Actual)	Interventional	1984-01-31	Completed
Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia[NCT00005313]		450 participants (Actual)	Observational	2001-04-30	Completed
[NCT00000553]	Phase 3	0 participants	Interventional	1994-09-30	Completed
HDL Increased Plaque Stabilization in the Elderly[NCT00127218]	Phase 3	145 participants (Actual)	Interventional	2003-09-30	Completed
A Multicenter Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)[NCT01152073]		79 participants (Actual)	Interventional	2009-10-31	Completed
[NCT00000483]		0 participants	Interventional	1981-06-30	Completed
A Prospective, Double-blinded, Randomised Study to Evaluate the Effects of Different Doses of Statin Treatment on Plaque Volume and Composition in Coronary Disease Determined by Virtual Histology Using Intravascular Ultrasound[NCT01200056]	Phase 4	40 participants (Actual)	Interventional	2007-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

(NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Major Coronary Events

Intervention	participants (Number)
ER Niacin/Laropiprant	807
Placebo	897

Non-fatal myocardial infarction (MI) or coronary death (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Major Vascular Event

Intervention	participants (Number)
ER Niacin/Laropiprant	668
Placebo	694

Non-fatal myocardial infarction or coronary death, non-fatal or fatal stroke, or revascularisation (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Mortality

Intervention	participants (Number)
ER Niacin/Laropiprant	1696
Placebo	1758

All-cause mortality (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Stroke

Intervention	participants (Number)
ER Niacin/Laropiprant	798
Placebo	732

Fatal or non-fatal (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12

Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12

Percent Change From Baseline in Triglycerides at Week 12

Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in High Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo

Intervention	participants (Number)
ER Niacin/Laropiprant	498
Placebo	499

Intervention	Percent (Least Squares Mean)
ER Niacin/Laropiprant + Run-in Statin	15.8
Run-in Statin Dose Doubled	0.2

Intervention	Percent (Least Squares Mean)
ER Niacin/Laropiprant + Run-in Statin	-10.0
Run-in Statin Dose Doubled	-5.5

Intervention	Percent (Median)
ER Niacin/Laropiprant + Run-in Statin	-17.6
Run-in Statin Dose Doubled	-4.0

After 12 weeks of treatment, to assess the increase of high-density lipoprotein cholesterol in patients with Type 2 diabetes when compared to placebo (NCT00485758)
Timeframe: Baseline and 12 Weeks

Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo

Intervention	Percent change at Wk 12 compared to Bl (Least Squares Mean)
Extended Release Niacin/Laropiprant	25.4
Placebo	2.2

After 12 Weeks of treatment, to assess the reduction of low-density lipoprotein cholesterol in patients with Type 2 diabetes when compared to placebo (NCT00485758)
Timeframe: Baseline and 12 Weeks

Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Triglycerides in Patients With Type 2 Diabetes When Compared to Placebo

Intervention	Percent change at Wk 12 compared to Bl (Least Squares Mean)
Extended Release Niacin/Laropiprant	-15.8
Placebo	2.1

after 12 weeks of treatment, to assess the reduction of triglycerides in patients with Type 2 diabetes when compared to placebo (NCT00485758)
Timeframe: Baseline and 12 Weeks

Change in Proteinuria

Lipoprotein Insulin Resistance Index (LIRI) After 12-14 Weeks Intervention, Compared to Baseline for Alpha-cyclodextrin (a-CD) and Placebo Groups After 12-14 Weeks, Compared to Baseline

Intervention	Percent change at Wk 12 compared to Bl (Median)
Extended Release Niacin/Laropiprant	-22.2
Placebo	2.3

Intervention	mg/dL (Number)
Extended Release Niacin	42
Placebo	63

LIRI was measured at the end of each study arm (a-CD or placebo). a-CD (2g) was taken orally three times a day for 12-14 weeks. Placebo (2 tablets) was taken orally for 12-14 weeks. There was a one-week washout period between each arm. (NCT01131299)
Timeframe: 24-28 weeks

Serum Glucose Levels After 12-14 Weeks Intervention, Compared to Baseline for Alpha-cyclodextrin (a-CD) and Placebo Groups After 12-14 Weeks, Compared to Baseline

Intervention	percentage (Mean)
a-CD	1.4
Placebo	1.6

Serum glucose levels was measured at the end of each study arm (a-CD or placebo). a-CD (2g) was taken orally three times a day for 12-14 weeks. Placebo (2 tablets) was taken orally for 12-14 weeks. There was a one-week washout period between each arm. (NCT01131299)
Timeframe: 24-28 weeks

Small LDL Particle Number (by NMR Spectrometry of Lipoproteins) After 12-14 Weeks Intervention, Compared to Baseline for Alpha-cyclodextrin (a-CD) and Placebo Groups After 12-14 Weeks, Compared to Baseline

Intervention	mg/dL (Mean)
a-CD	87
Placebo	88

Small LDL particle numbers were measured at the end of each study arm (a-CD or placebo). a-CD (2g) was taken orally three times a day for 12-14 weeks. Placebo (2 tablets) was taken orally for 12-14 weeks. There was a one-week washout period between each arm. (NCT01131299)
Timeframe: 24-28 weeks

Total Serum Cholesterol Levels for Alpha-cyclodextrin (a-CD) and Placebo Groups After 12-14 Weeks, Compared to Baseline

Intervention	nmol/L (Mean)
a-CD	365
Placebo	405

Total cholesterol levels were measured at the end of each study arm (a-CD or placebo). a-CD (2g) was taken orally three times a day for 12-14 weeks. Placebo (2 tablets) was taken orally for 12-14 weeks. There was a one-week washout period between each arm. (NCT01131299)
Timeframe: 24-28 weeks

Changes in Plaque Architecture and Composition Directly Measured by Magnetic Resonance Imaging (MRI) in the Aorta and Carotid Arteries

Intervention	mg/dL (Mean)
a-CD	180
Placebo	180

The primary endpoint is Changes in plaque architecture and composition directly measured by magnetic resonance imaging (MRI) in the aorta and carotid arteries. (NCT00127218)
Timeframe: 18 months

Multiple Combined Events ( Cardiovascular and Cerebrovascular Events as Well as Myocardial Revascularization)

Intervention	percentage of internal carotid artery (Mean)
Niacin Plus Statin	7
Placebo Plus Statin	5

Cerebrovascular events (newly diagnosed) such as Stroke and Myocardial revascularization (specifically coronary artery bypass grafting, percutaneous coronary interventions, carotid endarterectomy) were recorded (NCT00127218)
Timeframe: 18 months

Intervention	Participants (Count of Participants)
Any Statin Plus Niacin	6
Any Statin Plus Placebo	2

Article	Year
Activation of HCAR2 by niacin: benefits beyond lipid lowering. Pharmacogenomics, 2019, Volume: 20, Issue:16 Topics: Cholesterol, HDL; Coronary Disease; Genotype; Humans; Hypolipidemic Agents; Lipids; Niacin; Polymorp	2019
Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ (Clinical research ed.), 2014, Jul-18, Volume: 349 Topics: Amides; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Coronary Disease; Esters; Fib	2014
Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis. Heart (British Cardiac Society), 2015, Volume: 101, Issue:11 Topics: Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Disease; Fibric Acids; Humans; Hydro	2015
Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens. Current atherosclerosis reports, 2016, Volume: 18, Issue:2 Topics: Clinical Trials as Topic; Coronary Disease; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reducta	2016
Nicotinic acid: recent developments. Current opinion in cardiology, 2008, Volume: 23, Issue:4 Topics: Animals; Coronary Disease; Dyslipidemias; Humans; Lipid Metabolism; Niacin; Receptors, G-Protein-Cou	2008
Lipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia. Scandinavian cardiovascular journal : SCJ, 2008, Volume: 42, Issue:4 Topics: Cholesterol; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Humans; Hydroxymethylglu	2008
Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders. Expert review of cardiovascular therapy, 2008, Volume: 6, Issue:10 Topics: Animals; Cholesterol; Clinical Trials as Topic; Coronary Disease; Delayed-Action Preparations; Drug	2008
Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. Journal of the American College of Cardiology, 2009, Jan-27, Volume: 53, Issue:4 Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Female; Humans; Hydroxymethylg	2009
Lipid management in the geriatric patient. Endocrinology and metabolism clinics of North America, 2009, Volume: 38, Issue:1 Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Coronary Disea	2009
What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Current opinion in lipidology, 2009, Volume: 20, Issue:6 Topics: Coronary Disease; Delayed-Action Preparations; Drug Combinations; Flushing; Humans; Hypolipidemic Ag	2009
Triglycerides and HDL cholesterol: stars or second leads in diabetes? Diabetes care, 2009, Volume: 32 Suppl 2 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications	2009
Triglycerides and HDL cholesterol: stars or second leads in diabetes? Diabetes care, 2009, Volume: 32 Suppl 2 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications	2009
Triglycerides and HDL cholesterol: stars or second leads in diabetes? Diabetes care, 2009, Volume: 32 Suppl 2 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications	2009
Triglycerides and HDL cholesterol: stars or second leads in diabetes? Diabetes care, 2009, Volume: 32 Suppl 2 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications	2009
High-density lipoprotein and coronary heart disease: current and future therapies. Journal of the American College of Cardiology, 2010, Mar-30, Volume: 55, Issue:13 Topics: Acetyl-CoA C-Acetyltransferase; Animals; Apolipoprotein A-I; Biological Transport; Cholesterol Ester	2010
A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. Mayo Clinic proceedings, 2010, Volume: 85, Issue:4 Topics: Aspirin; Attitude to Health; Coronary Disease; Delayed-Action Preparations; Dose-Response Relationsh	2010
Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. Advances in therapy, 2010, Volume: 27, Issue:6 Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Drug Therapy, Combinat	2010
Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review. Postgraduate medicine, 2012, Volume: 124, Issue:1 Topics: Atorvastatin; Coronary Disease; Drug Therapy, Combination; Dyslipidemias; Flushing; Heptanoic Acids;	2012
Treating high density lipoprotein cholesterol (HDL-C): quantity versus quality. Current pharmaceutical design, 2013, Volume: 19, Issue:21 Topics: Animals; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coro	2013
Treatment of dyslipidaemia in high-risk patients: too little, too late. International journal of clinical practice. Supplement, 2002, Issue:130 Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combin	2002
Management of hypercholesterolaemia in the patient with diabetes. International journal of clinical practice. Supplement, 2002, Issue:130 Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, T	2002
[Treatment of high blood cholesterol in patients with coronary heart disease]. Nihon rinsho. Japanese journal of clinical medicine, 1994, Volume: 52 Suppl, Issue:Pt 1 Topics: Anion Exchange Resins; Bezafibrate; Clinical Trials as Topic; Coronary Disease; Humans; Hydroxymethy	1994
Therapy to reduce risk of coronary heart disease. Clinical cardiology, 2003, Volume: 26, Issue:1 Topics: Anion Exchange Resins; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Humans;	2003
Niacin and cholesterol: role in cardiovascular disease (review). The Journal of nutritional biochemistry, 2003, Volume: 14, Issue:6 Topics: Acyltransferases; Adipose Tissue; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Ch	2003
Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events. Current atherosclerosis reports, 2003, Volume: 5, Issue:5 Topics: Acute Disease; Algorithms; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Diab	2003
Niacin as a component of combination therapy for dyslipidemia. Mayo Clinic proceedings, 2003, Volume: 78, Issue:6 Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Delayed-Action Prepa	2003
CURRENT THERAPEUTIC CONCEPTS OF CEREBRAL AND MYOCARDIAL VASCULAR DISEASE. Angiology, 1964, Volume: 15 Topics: Acetazolamide; Anticoagulants; Brain Ischemia; Cerebrovascular Disorders; Coronary Disease; Histamin	1964
PHYSIOLOGY AND PHARMACOLOGY OF FIBRINOLYSIS. British medical bulletin, 1964, Volume: 20 Topics: Adrenocorticotropic Hormone; Adsorption; Anabolic Agents; Biomedical Research; Coronary Disease; Cor	1964
Antiatherothrombotic effects of nicotinic acid. Atherosclerosis, 2003, Volume: 171, Issue:1 Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Fibrinolytic Agents; Humans; Hydroxymethylglut	2003
The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin. The Annals of pharmacotherapy, 2004, Volume: 38, Issue:2 Topics: Adult; Aged; Cholesterol; Coronary Disease; Cost-Benefit Analysis; Female; Humans; Hyperlipidemias;	2004
Treating low HDL--from bench to bedside. Clinical biochemistry, 2004, Volume: 37, Issue:8 Topics: Animals; Cholesterol; Coronary Artery Disease; Coronary Disease; Endothelium, Vascular; Humans; Hype	2004
Improving lipid management--to titrate, combine or switch. International journal of clinical practice, 2004, Volume: 58, Issue:7 Topics: Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Red	2004
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. Current medical research and opinion, 2004, Volume: 20, Issue:8 Topics: Cholesterol, HDL; Coronary Disease; Female; Humans; Hypolipidemic Agents; Lipids; Male; Niacin; Prac	2004
Coadministration of multidrug therapy to achieve lipid goals. The Journal of the American Osteopathic Association, 2004, Volume: 104, Issue:9 Suppl 7 Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Coronary Disease; Drug Therapy, Combination; E	2004
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. Journal of the American College of Cardiology, 2005, Jan-18, Volume: 45, Issue:2 Topics: Adolescent; Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Femal	2005
The metabolic syndrome: modify root causes, treat risk factors. JAAPA : official journal of the American Academy of Physician Assistants, 2005, Volume: 18, Issue:3 Topics: Coronary Disease; Diabetes Mellitus, Type 2; Education, Medical, Continuing; Humans; Hydroxymethylgl	2005
[Niacin--an additive therapeutic approach for optimizing lipid profile]. Medizinische Klinik (Munich, Germany : 1983), 2005, Apr-15, Volume: 100, Issue:4 Topics: Cholesterol; Cholesterol, HDL; Controlled Clinical Trials as Topic; Coronary Disease; Drug Therapy,	2005
Cholesterol lowering in diabetes. New evidence supports aggressive LDL-C targets. Postgraduate medicine, 2005, Volume: 117, Issue:4 Topics: Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hyperlipid	2005
Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. Journal of internal medicine, 2005, Volume: 258, Issue:2 Topics: Adipose Tissue; Arteriosclerosis; Coronary Disease; Fatty Acids, Nonesterified; Fibrinolysis; Flushi	2005
What is the most effective strategy for managing diabetic dyslipidaemia? Atherosclerosis. Supplements, 2005, Volume: 6, Issue:3 Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Diabetic Angiopathies; Drug	2005
Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol. Journal of clinical hypertension (Greenwich, Conn.), 2006, Volume: 8, Issue:7 Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Combinations; D	2006
HDL elevators and mimetics--emerging therapies for atherosclerosis. Cardiovascular & hematological agents in medicinal chemistry, 2007, Volume: 5, Issue:1 Topics: Animals; Apolipoprotein A-I; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Casset	2007
Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:3 Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Va	2007
Dyslipidaemia in diabetic patients: time for a rethink. Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:5 Topics: Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Hu	2007
Hypertriglyceridemia and cardiovascular risk reduction. Clinical therapeutics, 2007, Volume: 29, Issue:5 Topics: Atherosclerosis; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Fatty Acids, Omega-3; Hu	2007
HDL-C in post-menopausal women: An important therapeutic target. International journal of cardiology, 2008, Mar-14, Volume: 124, Issue:3 Topics: Anticholesteremic Agents; Cholesterol, HDL; Clofibric Acid; Coronary Disease; Drug Therapy, Combinat	2008
Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. Journal of cardiovascular pharmacology, 2008, Volume: 51, Issue:4 Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Diabetes Complications; Humans	2008
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis. Circulation, 1984, Volume: 69, Issue:5 Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl	1984
Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens. Clinical cardiology, 1995, Volume: 18, Issue:6 Topics: Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Coronary Disease; Drug Therapy, Combinat	1995
Hyperlipidemia: perspectives in diagnosis and treatment. Southern medical journal, 1995, Volume: 88, Issue:4 Topics: Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Coronary Disease; Diet, Fat-Re	1995
Dyslipidemia and coronary artery disease. Clinical cardiology, 1994, Volume: 17, Issue:10 Topics: Arteriosclerosis; Cholesterol; Coronary Disease; Drug Therapy, Combination; Exercise; Gemfibrozil; H	1994
Impact of intensive lipid modulation on angiographically defined coronary disease: clinical implications. Southern medical journal, 1994, Volume: 87, Issue:2 Topics: Angiography; Clinical Trials as Topic; Colestipol; Coronary Disease; Humans; Hypercholesterolemia; L	1994
Atherosclerosis--reversal with therapy. The Western journal of medicine, 1993, Volume: 159, Issue:2 Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Clinical Trials as Topic; Coronary Angiography;	1993
Familial combined hyperlipidemia in children: clinical expression, metabolic defects, and management. The Journal of pediatrics, 1993, Volume: 123, Issue:2 Topics: Adolescent; Apolipoproteins B; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Cholesty	1993
Relationship between total mortality and cholesterol reduction as found by meta-regression analysis of randomized cholesterol-lowering trials. Controlled clinical trials, 1996, Volume: 17, Issue:1 Topics: Anticholesteremic Agents; Cholesterol; Clofibrate; Coronary Disease; Humans; Myocardial Infarction;	1996
Cholesterol management in patients with heart disease. Emphasizing secondary prevention to increase longevity. Postgraduate medicine, 1997, Volume: 102, Issue:2 Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Longevity; Lovastatin; Nia	1997
Nicotinic acid--the underused ally in the fight against coronary disease. Journal of cardiovascular risk, 1997, Volume: 4, Issue:3 Topics: Clinical Trials as Topic; Coronary Disease; Drug Utilization; Humans; Hypertriglyceridemia; Niacin;	1997
Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia. The American journal of cardiology, 1998, Feb-26, Volume: 81, Issue:4A Topics: Cholesterol, HDL; Cholesterol, VLDL; Clinical Trials as Topic; Consensus Development Conferences as	1998
Use of niacin, statins, and resins in patients with combined hyperlipidemia. The American journal of cardiology, 1998, Feb-26, Volume: 81, Issue:4A Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as To	1998
Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease. Angiology, 1998, Volume: 49, Issue:5 Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease;	1998
Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design. The Canadian journal of cardiology, 1998, Volume: 14 Suppl A Topics: Adult; Aged; Antioxidants; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Coronary	1998
Triglyceride as a risk factor for coronary artery disease. The American journal of cardiology, 1998, Nov-05, Volume: 82, Issue:9A Topics: Biomarkers; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus,	1998
[When statins alone are insufficient for lowering lipid levels. Efficacy and risks of lipid lowering combination therapies, in particular, that of statin-fibrate combination]. Der Internist, 1999, Volume: 40, Issue:12 Topics: Coronary Disease; Drug Therapy, Combination; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Ni	1999
Identification and treatment of hypertriglyceridemia as a risk factor for coronary heart disease. Current cardiology reports, 1999, Volume: 1, Issue:3 Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Humans; Hypertriglyceridemia; Hypolipi	1999
Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. QJM : monthly journal of the Association of Physicians, 2000, Volume: 93, Issue:9 Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Bezafibrate; Cholesterol; Cholestero	2000
Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. The American journal of cardiology, 2000, Mar-01, Volume: 85, Issue:5 Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans;	2000
Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? Current opinion in lipidology, 2000, Volume: 11, Issue:6 Topics: Adult; Aged; Algorithms; Animals; Body Mass Index; Cholesterol, HDL; Coronary Disease; Estrogens; Hu	2000
Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol. Current atherosclerosis reports, 2000, Volume: 2, Issue:1 Topics: Anticholesteremic Agents; Cholesterol, HDL; Coronary Disease; Estrogens; Exercise; Humans; Hypolipid	2000
Does hypertriglyceridemia increase risk for CAD? Growing evidence suggests it plays a role. Postgraduate medicine, 2000, Volume: 108, Issue:7 Topics: Coronary Disease; Diabetes Complications; Evidence-Based Medicine; Humans; Hypertriglyceridemia; Hyp	2000
The emerging role of HDL cholesterol. Is it time to focus more energy on raising high-density lipoprotein levels? Postgraduate medicine, 2000, Volume: 108, Issue:7 Topics: Alcohol Drinking; Body Weight; Cholesterol; Cholesterol, HDL; Coronary Disease; Dietary Fats; Estrog	2000
[Nicotinic acid and the derivative]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 3 Topics: Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Hum	2001
Dyslipidemia, gender, and the role of high-density lipoprotein cholesterol: implications for therapy. The American journal of cardiology, 2000, Dec-21, Volume: 86, Issue:12A Topics: Adult; Aging; Cholesterol, HDL; Coronary Disease; Female; Humans; Hyperlipidemias; Male; Menopause;	2000
Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review. The American journal of cardiology, 2000, Dec-21, Volume: 86, Issue:12A Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Drug Combinations; Female; Gemfibrozil	2000
Clinical treatment of dyslipidemia: practice patterns and missed opportunities. The American journal of cardiology, 2000, Dec-21, Volume: 86, Issue:12A Topics: Age Distribution; Aged; Coronary Disease; Female; Humans; Hyperlipidemias; Male; Medical Records Sys	2000
Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. Current medical research and opinion, 2001, Volume: 17, Issue:1 Topics: Atorvastatin; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Heptanoic Acids; Humans; Hyd	2001
Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century. Current atherosclerosis reports, 2001, Volume: 3, Issue:5 Topics: Coronary Disease; Drug Interactions; Drug Therapy, Combination; Humans; Hypercholesterolemia; Hyperl	2001
Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol. Current opinion in pharmacology, 2001, Volume: 1, Issue:2 Topics: Acids, Acyclic; Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Epidemiologic Studies;	2001
The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials. The American journal of cardiology, 2001, Dec-20, Volume: 88, Issue:12A Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Dis	2001
Taking stock of antioxidants. Harvard health letter, 2002, Volume: 27, Issue:4 Topics: Anticholesteremic Agents; Antioxidants; Coronary Disease; Drug Combinations; Drug Evaluation, Precli	2002
Managing dyslipidemia in the high-risk patient. The American journal of cardiology, 2002, Mar-07, Volume: 89, Issue:5A Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Tria	2002
Should pediatric patients with hyperlipidemia receive drug therapy? Paediatric drugs, 2002, Volume: 4, Issue:4 Topics: Anticholesteremic Agents; Child; Cholestyramine Resin; Coronary Disease; Fatty Acids, Omega-3; Human	2002
Management of hypercholesterolaemia in postmenopausal women. Drugs & aging, 2002, Volume: 19, Issue:3 Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diet; Drug The	2002
The triglyceride connection in atherosclerosis. The Annals of pharmacotherapy, 1992, Volume: 26, Issue:9 Topics: Alcohol Drinking; Arteriosclerosis; Coronary Disease; Diabetes Complications; Diet; Exercise; Humans	1992
Cholesterol-lowering drugs as cardioprotective agents. The American journal of cardiology, 1992, Dec-21, Volume: 70, Issue:21 Topics: Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA	1992
Nicotinic acid for the treatment of hyperlipoproteinemia. Journal of clinical pharmacology, 1991, Volume: 31, Issue:7 Topics: Anticholesteremic Agents; Coronary Disease; Drug Therapy, Combination; Humans; Hyperlipoproteinemia	1991
Drug therapy in dyslipidemia. Scandinavian journal of clinical and laboratory investigation. Supplementum, 1990, Volume: 199 Topics: Anticholesteremic Agents; Bile Acids and Salts; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA	1990
Drug treatment of dyslipoproteinemia. Endocrinology and metabolism clinics of North America, 1990, Volume: 19, Issue:2 Topics: Bile Acids and Salts; Clofibrate; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Humans;	1990
Pharmacological intervention for altering lipid metabolism. Drugs, 1990, Volume: 40 Suppl 1 Topics: Animals; Cholestyramine Resin; Coronary Disease; Gemfibrozil; Humans; Lipid Metabolism; Lipids; Niac	1990
Secondary prevention of coronary disease with lipid-lowering drugs. Lancet (London, England), 1989, Mar-04, Volume: 1, Issue:8636 Topics: Adult; Cholesterol; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Humans; Hypolip	1989
Reducing cardiac deaths with hypolipidemic drugs. Postgraduate medicine, 1987, Nov-01, Volume: 82, Issue:6 Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Feeding Behavior; Gemfi	1987
The diagnosis and management of hyperlipidemia. Disease-a-month : DM, 1986, Volume: 32, Issue:5 Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibr	1986
Antihyperlipidemic properties of beta-pyridylcarbinol. A review of preclinical studies. Life sciences, 1985, Nov-25, Volume: 37, Issue:21 Topics: Adipose Tissue; Adrenal Cortex; Animals; Blood Glucose; Cholesterol; Cholesterol, Dietary; Coronary	1985

Article	Year
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study. Circulation. Genomic and precision medicine, 2018, Volume: 11, Issue:2 Topics: Aged; Coronary Disease; Female; Humans; Hypolipidemic Agents; Indoles; Lipoprotein(a); Male; Middle	2018
Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. International journal of clinical practice, 2013, Volume: 67, Issue:4 Topics: Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Meth	2013
Pharmacological measures to increase HDL-C among high risk isolated low HDL cases: a randomized study amongst north Indians. The Indian journal of medical research, 2013, Volume: 138, Issue:6 Topics: Aged; Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Fenofibrate; Heptanoic Acids; Humans	2013
Extended-release niacin or ezetimibe and carotid intima-media thickness. The New England journal of medicine, 2009, Nov-26, Volume: 361, Issue:22 Topics: Aged; Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Co	2009
Extended-release niacin or ezetimibe and carotid intima-media thickness. The New England journal of medicine, 2009, Nov-26, Volume: 361, Issue:22 Topics: Aged; Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Co	2009
Extended-release niacin or ezetimibe and carotid intima-media thickness. The New England journal of medicine, 2009, Nov-26, Volume: 361, Issue:22 Topics: Aged; Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Co	2009
Extended-release niacin or ezetimibe and carotid intima-media thickness. The New England journal of medicine, 2009, Nov-26, Volume: 361, Issue:22 Topics: Aged; Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Co	2009
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. Journal of the American College of Cardiology, 2010, Jun-15, Volume: 55, Issue:24 Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Artery, Common; Cholesterol, HD	2010
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Doub	2011
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Doub	2011
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Doub	2011
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Doub	2011
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Doub	2011
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Doub	2011
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Doub	2011
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Doub	2011
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Doub	2011
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Doub	2011
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Doub	2011
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Doub	2011
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Doub	2011
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Doub	2011
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Doub	2011
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Doub	2011
Determinants of lipid goal achievement in patients on extended-release nicotinic acid/laropiprant in primary care clinical practice. Current medical research and opinion, 2013, Volume: 29, Issue:1 Topics: Age Factors; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Disease	2013
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation, 2004, Dec-07, Volume: 110, Issue:23 Topics: Aged; Biomarkers; Carotid Artery Diseases; Carotid Artery, Common; Cholesterol, HDL; Coronary Diseas	2004
A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Annals of internal medicine, 2005, Jan-18, Volume: 142, Issue:2 Topics: Aged; Cholesterol, HDL; Cholestyramine Resin; Coronary Angiography; Coronary Disease; Disease Progre	2005
[Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification]. Zhonghua yi xue za zhi, 2006, Sep-12, Volume: 86, Issue:34 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coron	2006
Pharmacological trials: primary and secondary prevention of coronary heart disease. Preventive medicine, 1983, Volume: 12, Issue:1 Topics: Aspirin; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Colestipol; Coronary Disease; D	1983
Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS Trial. Familial Atherosclerosis Treatment Study. Annals of the New York Academy of Sciences, 1995, Jan-17, Volume: 748 Topics: Adult; Colestipol; Coronary Disease; Diet, Fat-Restricted; Humans; Lovastatin; Male; Middle Aged; Ni	1995
A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS). Controlled clinical trials, 1995, Volume: 16, Issue:1 Topics: Adult; Aged; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Fol	1995
[Induracin, prolonged-action nicotinic acid, in the treatment of atherogenic dyslipoproteinemia]. Klinicheskaia meditsina, 1994, Volume: 72, Issue:3 Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL;	1994
Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. Journal of the American College of Cardiology, 1994, Mar-15, Volume: 23, Issue:4 Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Apolipoproteins B; Cholesterol, LDL; Colestip	1994
[The use of Enduracin--a prolonged-action form of nicotinic acid--in correcting atherogenic dyslipidemias]. Kardiologiia, 1993, Volume: 33, Issue:10 Topics: Adult; Aged; Arteriosclerosis; Coronary Disease; Delayed-Action Preparations; Double-Blind Method; D	1993
Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B. Circulation, 1993, Volume: 88, Issue:6 Topics: Adult; Apolipoproteins B; Colestipol; Coronary Disease; Coronary Vessels; Double-Blind Method; Exerc	1993
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis. The International journal of artificial organs, 1995, Volume: 18, Issue:12 Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol,	1995
Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl. The American journal of cardiology, 1997, Oct-01, Volume: 80, Issue:7 Topics: Aged; Brachial Artery; Cholestyramine Resin; Coronary Disease; Double-Blind Method; Drug Therapy, Co	1997
Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design. The Canadian journal of cardiology, 1998, Volume: 14 Suppl A Topics: Adult; Aged; Antioxidants; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Coronary	1998
Effect of niacin and etofibrate association on subjects with coronary artery disease and serum high-density lipoprotein cholesterol <35 mg/dl. The American journal of cardiology, 1999, Jan-01, Volume: 83, Issue:1 Topics: Anticholesteremic Agents; Cholesterol, HDL; Clofibric Acid; Coronary Disease; Delayed-Action Prepara	1999
[Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study]. Zeitschrift fur Kardiologie, 1999, Volume: 88, Issue:8 Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol	1999
Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Archives of internal medicine, 2000, Apr-24, Volume: 160, Issue:8 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Doub	2000
Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). The American journal of cardiology, 2000, Dec-15, Volume: 86, Issue:12 Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Chemopreven	2000
Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation, 2001, Feb-13, Volume: 103, Issue:6 Topics: Analysis of Variance; Cholesterol, HDL; Colestipol; Coronary Angiography; Coronary Disease; Drug The	2001
Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arteriosclerosis, thrombosis, and vascular biology, 2001, Volume: 21, Issue:8 Topics: Adult; Aged; Antioxidants; Ascorbic Acid; beta Carotene; Cholesterol, HDL; Cholesterol, LDL; Coronar	2001
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22 Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas	2001
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22 Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas	2001
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22 Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas	2001
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22 Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas	2001
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22 Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas	2001
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22 Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas	2001
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22 Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas	2001
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22 Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas	2001
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22 Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas	2001
Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy. American heart journal, 2002, Volume: 143, Issue:3 Topics: Adult; Aged; Analysis of Variance; Coronary Disease; Drug Therapy, Combination; Female; Humans; Hype	2002
Cholesterol-lowering drugs as cardioprotective agents. The American journal of cardiology, 1992, Dec-21, Volume: 70, Issue:21 Topics: Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA	1992
Coronary drug project: experience with niacin. Coronary Drug Project Research Group. European journal of clinical pharmacology, 1991, Volume: 40 Suppl 1 Topics: Adult; Coronary Disease; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Niacin	1991
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England journal of medicine, 1990, Nov-08, Volume: 323, Issue:19 Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coro	1990
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England journal of medicine, 1990, Nov-08, Volume: 323, Issue:19 Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coro	1990
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England journal of medicine, 1990, Nov-08, Volume: 323, Issue:19 Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coro	1990
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England journal of medicine, 1990, Nov-08, Volume: 323, Issue:19 Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coro	1990
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England journal of medicine, 1990, Nov-08, Volume: 323, Issue:19 Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coro	1990
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England journal of medicine, 1990, Nov-08, Volume: 323, Issue:19 Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coro	1990
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England journal of medicine, 1990, Nov-08, Volume: 323, Issue:19 Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coro	1990
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England journal of medicine, 1990, Nov-08, Volume: 323, Issue:19 Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coro	1990
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England journal of medicine, 1990, Nov-08, Volume: 323, Issue:19 Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coro	1990
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England journal of medicine, 1990, Nov-08, Volume: 323, Issue:19 Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coro	1990
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England journal of medicine, 1990, Nov-08, Volume: 323, Issue:19 Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coro	1990
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England journal of medicine, 1990, Nov-08, Volume: 323, Issue:19 Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coro	1990
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England journal of medicine, 1990, Nov-08, Volume: 323, Issue:19 Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coro	1990
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England journal of medicine, 1990, Nov-08, Volume: 323, Issue:19 Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coro	1990
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England journal of medicine, 1990, Nov-08, Volume: 323, Issue:19 Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coro	1990
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England journal of medicine, 1990, Nov-08, Volume: 323, Issue:19 Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angiography; Coro	1990
Secondary prevention of coronary disease with lipid-lowering drugs. Lancet (London, England), 1989, Mar-04, Volume: 1, Issue:8636 Topics: Adult; Cholesterol; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Humans; Hypolip	1989

Article	Year
(8) Cardiovascular disease and risk management. Diabetes care, 2015, Volume: 38 Suppl Topics: Antihypertensive Agents; Cardiovascular Diseases; Coronary Disease; Diabetes Complications; Diabetes	2015
(8) Cardiovascular disease and risk management. Diabetes care, 2015, Volume: 38 Suppl Topics: Antihypertensive Agents; Cardiovascular Diseases; Coronary Disease; Diabetes Complications; Diabetes	2015
(8) Cardiovascular disease and risk management. Diabetes care, 2015, Volume: 38 Suppl Topics: Antihypertensive Agents; Cardiovascular Diseases; Coronary Disease; Diabetes Complications; Diabetes	2015
(8) Cardiovascular disease and risk management. Diabetes care, 2015, Volume: 38 Suppl Topics: Antihypertensive Agents; Cardiovascular Diseases; Coronary Disease; Diabetes Complications; Diabetes	2015
Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011. Journal of the American College of Cardiology, 2015, Oct-27, Volume: 66, Issue:17 Topics: Adult; Anticholesteremic Agents; Coronary Disease; Drug Utilization; Ezetimibe; Humans; Hyperlipidem	2015
Diabetic dyslipidemia: a practical guide to therapy. The Journal of family practice, 2008, Volume: 57, Issue:6 Topics: Clofibric Acid; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias;	2008
Reducing coronary risk by raising HDL-cholesterol: risk modelling the addition of nicotinic acid to existing therapy. Current medical research and opinion, 2008, Volume: 24, Issue:9 Topics: Cholesterol, HDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin;	2008
Reshaping the dyslipidemia management paradigm. Postgraduate medicine, 2003, Volume: 114, Issue:2 Suppl Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Dyslipidemias; Fe	2003
Achieving cholesterol goals. Current and future drug therapies. Postgraduate medicine, 2003, Volume: 114, Issue:2 Suppl Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dy	2003
CHD risk equivalents and the metabolic syndrome. Trial evidence supports aggressive management. Postgraduate medicine, 2003, Volume: 114, Issue:2 Suppl Topics: Adult; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Diabetes Complications; Dyslipidemias; Fe	2003
[Significance of HDL cholesterol increase for the risk reduction. Methods of intervention. recommendations of experts]. Kardiologia polska, 2005, Volume: 62 Suppl 2 Topics: Acyl Coenzyme A; Adult; Anticholesteremic Agents; Cholesterol, HDL; Clofibric Acid; Coronary Disease	2005
The HALTS trial--halting atherosclerosis or halted too early? The New England journal of medicine, 2009, Nov-26, Volume: 361, Issue:22 Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Coronary	2009
Statin therapy with ezetimibe or niacin in high-risk patients. The New England journal of medicine, 2009, Nov-26, Volume: 361, Issue:22 Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Coronary	2009
Lipid disorders. JAAPA : official journal of the American Academy of Physician Assistants, 2009, Volume: 22, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary D	2009
[Statin plus niacin or ezetimibe? What combination for which patients?]. MMW Fortschritte der Medizin, 2009, Dec-03, Volume: 151, Issue:49-50 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Artery Diseases; Coronary Disease; Dr	2009
Niacin compared with ezetimibe. The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Blood Pressure; Carotid Arteries; Coronary Disease; Drug Thera	2010
Niacin compared with ezetimibe. The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, LDL; Coronary Disease; Drug The	2010
Niacin compared with ezetimibe. The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Coronary Disease; Drug Therapy, Combination;	2010
Niacin compared with ezetimibe. The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11 Topics: Anticholesteremic Agents; Azetidines; Blood Glucose; Carotid Arteries; Coronary Disease; Diabetes Me	2010
I have had trouble controlling my cholesterol with a statin alone. Should I consider prescription niacin? The Johns Hopkins medical letter health after 50, 2010, Volume: 21, Issue:12 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination;	2010
Ezetimibe and recent clinical trials: a look on the bright side. Expert opinion on drug safety, 2010, Volume: 9, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-	2010
Trial puts niacin--and cholesterol dogma--in the line of fire. Nature medicine, 2011, Jul-07, Volume: 17, Issue:7 Topics: Cholesterol, HDL; Coronary Disease; Drug Approval; Fenofibrate; Humans; Hypolipidemic Agents; Niacin	2011
Update on therapies targeting HDL: the mystery continues. Current opinion in lipidology, 2011, Volume: 22, Issue:6 Topics: Animals; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Coronary Disease; Early Termination	2011
[Secondary coronary heart disease prevention. Will CEPT inhibitors be the next breakthrough?]. MMW Fortschritte der Medizin, 2011, Dec-08, Volume: 153, Issue:49-50 Topics: Acute Coronary Syndrome; Amides; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol,	2011
Serum taurine and risk of coronary heart disease: a prospective, nested case-control study. European journal of nutrition, 2013, Volume: 52, Issue:1 Topics: Adult; Aged; Animals; Case-Control Studies; Cholesterol; Coronary Disease; Diet; Dietary Fats; Dieta	2013
Avoid no-flush niacin in favor of the prescription version. Follow certain steps to reduce the flushing effects of prescription niacin. Heart advisor, 2010, Volume: 13, Issue:11 Topics: Attitude to Health; Cholesterol, HDL; Coronary Disease; Dose-Response Relationship, Drug; Flushing;	2010
Niacin: its value in raising HDL cholesterol is being questioned. Heart advisor, 2011, Volume: 14, Issue:10 Topics: Attitude to Health; Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Rela	2011
The rationale for combination therapy. The American journal of cardiology, 2002, Nov-20, Volume: 90, Issue:10B Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combin	2002
Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction. The American journal of cardiology, 2002, Nov-20, Volume: 90, Issue:10B Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Humans; Hyd	2002
Existing and investigational combination drug therapy for high-density lipoprotein cholesterol. The American journal of cardiology, 2002, Nov-20, Volume: 90, Issue:10B Topics: Anticholesteremic Agents; Cholesterol, HDL; Coronary Disease; Drug Therapy, Combination; Estrogens;	2002
Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy. Journal of cardiovascular risk, 2002, Volume: 9, Issue:6 Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coronary Disease; Drug	2002
Niacin and the National Cholesterol Education Program Adult Treatment Panel III Guidelines: case studies. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2003, Jul-01, Volume: 60, Issue:13 Suppl 2 Topics: Aspirin; Atenolol; Blood Chemical Analysis; Coronary Disease; Female; Humans; Hyperlipidemias; Hyper	2003
Nicotinic acid in the treatment of ischaemic heart-disease. Lancet (London, England), 1960, Sep-24, Volume: 2, Issue:7152 Topics: Coronary Artery Disease; Coronary Disease; Myocardial Ischemia; Niacin; Nicotinic Acids	1960
[The use of nicotinic acid in patients with coronary insufficiency]. Terapevticheskii arkhiv, 1961, Volume: 33 Topics: Cardiotonic Agents; Coronary Artery Disease; Coronary Disease; Niacin; Nicotinic Acids	1961
[Preliminary clinical observations on treatment with a monoamine oxidase antagonist in coronary diseases and in other disease states]. Minerva medica, 1959, Dec-26, Volume: 50 Topics: Anti-Arrhythmia Agents; Coronary Disease; Enzyme Inhibitors; Humans; Monoamine Oxidase; Niacin; Nico	1959
Triparanol and nicotinic acid in the management of hypercholesterolaemia. Australasian annals of medicine, 1962, Volume: 11 Topics: Anticholesteremic Agents; Cardiotonic Agents; Cholesterol; Coronary Disease; Disease Management; Hyp	1962
[Pharmacological properties of the preparation "Nikatol"]. Fiziolohichnyi zhurnal, 1963, Volume: 9(1) Topics: Arteriosclerosis; Cholesterol; Coronary Disease; Humans; Niacin; Nicotinic Acids	1963
[Contribution to preventive cardiology]. Medizinische Klinik, 1963, May-17, Volume: 58 Topics: Coronary Disease; Diet; Fats, Unsaturated; Heparin; Hypercholesterolemia; Ion Exchange Resins; Neomy	1963
[Effect of Lipokapsul on the serum lipids in arteriosclerosis (with reference to different diet forms)]. Die Medizinische Welt, 1962, Sep-01, Volume: 35 Topics: Arteriosclerosis; Coronary Disease; Diet; Diet Therapy; Fatty Acids; Fatty Acids, Essential; Humans;	1962
A LONG TERM STUDY OF THE EFFECT OF NICOTINIC ACID MEDICATION ON HYPERCHOLESTEREMIA. The American journal of the medical sciences, 1963, Volume: 246 Topics: Acanthosis Nigricans; Arteriosclerosis; Coronary Disease; Diabetes Mellitus; Geriatrics; Humans; Hyp	1963
[COAGULATION AND ANTICOAGULATION FACTORS IN THE BLOOD AND THEIR ALTERATION IN DISORDERS OF CORONARY CIRCULATION]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1963, Aug-01, Volume: 18 Topics: Angina Pectoris; Blood Coagulation; Blood Coagulation Disorders; Blood Coagulation Factors; Coronary	1963
[CONTRIBUTION TO THE BIOCHEMICAL DIRECTOR OF THERAPY IN MYOCARDIAL INSUFFICIENCY]. La Clinica terapeutica, 1963, Oct-31, Volume: 27 Topics: Adenine Nucleotides; Arginine; Coronary Disease; Geriatrics; Hexosephosphates; Hypoxia; Myocardium;	1963
PLASMA TRIGLYCERIDE CONCENTRATION AND PLASMA FREE FATTY ACID CHANGES IN RESPONSE TO NOREPINEPHRINE IN MAN. The Journal of clinical investigation, 1964, Volume: 43 Topics: Blood Pressure; Coronary Disease; Fatty Acids; Fatty Acids, Nonesterified; Glycerides; Lipids; Niaci	1964
[7-(3-(METHYL-OXYETHYLAMINE)-2-OXYPROPYL)-1, 3-DIMETHYL-XANTHINE NICOTINATE IN CHRONIC OBLITERATING ANGIOPATHIES]. La Semana medica, 1963, Nov-28, Volume: 123 Topics: Arteriosclerosis; Arteriosclerosis Obliterans; Cholesterol; Coronary Disease; Humans; Intracranial A	1963
MANAGEMENT OF HYPERCHOLESTEROLEMIA. GP, 1964, Volume: 29 Topics: Cerebral Hemorrhage; Cholagogues and Choleretics; Coronary Disease; Diet; Diet Therapy; Hypercholest	1964
[PROLONGED TREATMENT WITH LARGE DOSES OF NICOTINIC ACID IN CORONARY ARTERIOSCLEROSIS]. Medicina interna, 1964, Volume: 16 Topics: Coronary Artery Disease; Coronary Disease; Humans; Hyperlipidemias; Niacin; Nicotinic Acids	1964
[COAGULATION AND ANTICOAGULATION SYSTEM OF THE BLOOD AND ITS REACTION TO CORONARY CIRCULATION DISORDERS]. Terapevticheskii arkhiv, 1964, Volume: 36 Topics: Angina Pectoris; Anticoagulants; Blood Coagulation Disorders; Blood Coagulation Tests; Coronary Circ	1964
[INDIRECT FIBRINOLYTIC AND ANTICOAGULANT TREATMENT OF THROMBOSIS]. Il Policlinico. Sezione pratica, 1964, May-25, Volume: 71 Topics: Anticoagulants; Arteriosclerosis Obliterans; Arteritis; Coronary Disease; Diabetic Angiopathies; Eth	1964
[ON THE THERAPY OF CORONARY INSUFFICIENCY]. Therapie der Gegenwart, 1964, Volume: 103 Topics: Anticoagulants; Coronary Artery Disease; Coronary Disease; Digitalis Glycosides; Dipyridamole; Drug	1964
[A CONTRIBUTION TO COMPLAMIN TREATMENT]. Therapie der Gegenwart, 1964, Volume: 103 Topics: Arteriosclerosis Obliterans; Biomedical Research; Cardiovascular Diseases; Coronary Disease; Drug Th	1964
[COMPLAMINE TREATMENT OF PATIENTS WITH INCREASED SERUM CHOLESTEROL VALUES]. Svenska lakartidningen, 1964, Sep-09, Volume: 61 Topics: Cholesterol; Coronary Disease; Humans; Hypercholesterolemia; Hyperlipidemias; Niacin; Nicotinic Acid	1964
[CLINICAL OBSERVATIONS AND THERAPEUTIC RESULTS IN SUBJECTS WITH ISCHEMIC CARDIOPATHY TREATED WITH AN ENZYME COMPLEX ASSOCIATED WITH A VASODILATOR DRUG]. Gazzetta medica italiana, 1964, Volume: 123 Topics: Adenosine Triphosphate; Coronary Disease; Drug Therapy; Electrocardiography; Flavin Mononucleotide;	1964
[ON THE CLINICAL VALUE OF COLLATERAL TROPHO-ENZYMATIC THERAPY IN ACUTE AND CHRONIC HEART DISEASES]. Gazzetta medica italiana, 1964, Volume: 123 Topics: Coenzymes; Coronary Disease; Heart Diseases; Humans; Hypertension; Khellin; Niacin; Niacinamide; Pul	1964
[THE EFFECT OF NICOTINIC ACID ON THE METABOLISM OF LIPIDS, ESPECIALLY THE BLOOD CHOLESTEROL IN CASES OF ARTERIOSCLEROSIS]. Polski tygodnik lekarski (Warsaw, Poland : 1960), 1964, Sep-14, Volume: 19 Topics: Arteriosclerosis; Biomedical Research; Blood Chemical Analysis; Blood Proteins; Cholesterol; Coronar	1964
[FIRST EXPERIENCES ON THE THERAPEUTIC ACTIVITY OF M-INOSITOL HEXANICOTINATE AND KALLIKREIN IN PERIPHERAL VASCULAR DISEASES AND IN CORONARY DISEASE]. Il Policlinico. Sezione pratica, 1964, Dec-21, Volume: 71 Topics: Coronary Disease; Electric Impedance; Electrocardiography; Humans; Kallikreins; Niacin; Nicotinic Ac	1964
PREVENTION OF CORONARY THROMBOSIS: CLINICAL OBSERVATIONS FOR 1 TO 10 YEARS. Current therapeutic research, clinical and experimental, 1965, Volume: 7 Topics: Biomedical Research; Coronary Disease; Coronary Thrombosis; Drug Therapy; Humans; Niacin; Nicotinic	1965
[NEW POSSIBILITIES IN THE DIAGNOSIS AND MEASURES FOR DRUG CONTROL OF DEGENERATIVE VASCULAR DISEASES]. Die Medizinische Welt, 1964, Oct-17, Volume: 42 Topics: Anticholesteremic Agents; Arteriosclerosis; Blood Chemical Analysis; Cardiovascular Diseases; Corona	1964
Nicotinic acid therapy in patints with coronary disease. The New Zealand medical journal, 1960, Volume: 59 Topics: Anti-Arrhythmia Agents; Coronary Disease; Diuretics; Niacin; Nicotinic Acids	1960
[First results with nialamide in cardiovascular therapy]. Minerva medica, 1959, Dec-26, Volume: 50 Topics: Anti-Arrhythmia Agents; Coronary Disease; Humans; Myocardial Infarction; Niacin; Nialamide; Nicotini	1959
Nicotinic acid therapy in coronary disease. American heart journal, 1962, Volume: 63 Topics: Anti-Arrhythmia Agents; Cardiotonic Agents; Coronary Disease; Humans; Niacin; Nicotinic Acids	1962
[New drug against lipid disorders. HDL level rises 30%]. MMW Fortschritte der Medizin, 2003, Sep-25, Volume: 145, Issue:39 Topics: Cholesterol, HDL; Coronary Disease; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Life Styl	2003
The role of treatment to increase HDL-cholesterol and decrease triglyceride concentrations in prevention of coronary heart disease in Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2004, Volume: 21 Suppl 4 Topics: Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hy	2004
Utility of currently available modes of therapy in reaching lipid goals. The Journal of the American Osteopathic Association, 2004, Volume: 104, Issue:9 Suppl 7 Topics: Anticholesteremic Agents; Clofibric Acid; Coronary Disease; Fish Oils; Humans; Hydroxymethylglutaryl	2004
Atherosclerosis imaging and the future of lipid management. Circulation, 2004, Dec-07, Volume: 110, Issue:23 Topics: Aged; Carotid Artery Diseases; Carotid Artery, Common; Cholesterol, HDL; Coronary Disease; Drug Ther	2004
Lipid-lowering drugs. Nursing older people, 2004, Volume: 16, Issue:9 Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Ezetimibe; Fatty Acids	2004
Summaries for patients. Targeting cholesterol treatment toward increasing high-density lipoprotein levels. Annals of internal medicine, 2005, Jan-18, Volume: 142, Issue:2 Topics: Aged; Cholesterol, HDL; Cholestyramine Resin; Coronary Angiography; Coronary Disease; Disease Progre	2005
Niaspan: new hope for heart patients. Drug discovery today, 2005, Jan-01, Volume: 10, Issue:1 Topics: Clinical Trials as Topic; Coronary Disease; Drug Combinations; Humans; Hypolipidemic Agents; Niacin;	2005
Nicotinic acid and HDL-C reduction. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2005, Volume: 95, Issue:2 Topics: Cholesterol, HDL; Coronary Disease; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Red	2005
Lipid metabolism. Current opinion in lipidology, 2005, Volume: 16, Issue:6 Topics: Cholesterol, HDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Me	2005
Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future? The American journal of cardiology, 2005, Nov-07, Volume: 96, Issue:9A Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clofibric	2005
American Heart Association - Scientific Sessions 2006. Cell therapies for ischemic tissues and treatments for lipid metabolism disorders. IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:1 Topics: Animals; Cell- and Tissue-Based Therapy; Cholesterol, LDL; Coronary Disease; Endothelial Cells; Eryt	2007
Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective. International journal of clinical practice, 2007, Volume: 61, Issue:11 Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coronary Disease; Cost-Benefit Analysis; D	2007
Nicotinic acid, free fatty acids and myocardial function during coronary occlusion and reperfusion in the dog. The Journal of pharmacology and experimental therapeutics, 1984, Volume: 231, Issue:3 Topics: Animals; Coronary Circulation; Coronary Disease; Dogs; Fatty Acids, Nonesterified; Female; Heart; Ma	1984
[Effect of antibradykinin preparations and nicotinic acid on the microcirculation and blood oxygen balance of ischemic heart disease patients in the initial stage of heart failure]. Kardiologiia, 1983, Volume: 23, Issue:8 Topics: Adult; Aged; Bradykinin; Chromonar; Coronary Disease; Diphenhydramine; Dipyrone; Drug Therapy, Combi	1983
Protection of myocardium by the compensatory mechanism of coronary collaterals after total occlusion of major coronary arteries shown in patients with familial hypercholesterolemia. American heart journal, 1982, Volume: 104, Issue:1 Topics: Adult; Arterial Occlusive Diseases; Cholesterol; Cholesterol, Dietary; Cholesterol, LDL; Colestipol;	1982
Use of neural networks in predicting the risk of coronary artery disease. Computers and biomedical research, an international journal, 1995, Volume: 28, Issue:1 Topics: Adult; Cholesterol; Colestipol; Coronary Artery Disease; Coronary Disease; Diet, Fat-Restricted; Fol	1995
Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician. Archives of internal medicine, 1994, Jul-25, Volume: 154, Issue:14 Topics: Coronary Disease; Humans; Hypercholesterolemia; Lipoproteins; Lovastatin; Niacin	1994
Lipoprotein(a) and coronary heart disease. Chemistry and physics of lipids, 1994, Volume: 67-68 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apolipoproteins; Apoprotein(a); Child; Coronary Disease;	1994
Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. The American journal of medicine, 1996, Volume: 100, Issue:2 Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Colestipol; Coronary Disease; Female; Gemfibrozil;	1996
Elevated lipoprotein(a) and premature coronary heart disease. JAMA, 1997, Jan-15, Volume: 277, Issue:3 Topics: Coronary Disease; Humans; Hypolipidemic Agents; Lipoprotein(a); Niacin	1997
Treatment of the patient with primary familial heterozygous hypercholesterolemia. The Journal of cardiovascular nursing, 1995, Volume: 9, Issue:2 Topics: Aged; Colestipol; Coronary Disease; Diet, Fat-Restricted; Drug Therapy, Combination; Exercise; Femal	1995
Choice of lipid-lowering drugs. The Medical letter on drugs and therapeutics, 1998, Dec-18, Volume: 40, Issue:1042 Topics: Animals; Cholestyramine Resin; Coronary Disease; Estrogen Replacement Therapy; Gemfibrozil; Humans;	1998
Immunoadsorption and dextran sulfate cellulose LDL-apheresis for severe hypercholesterolemia: the Rogosin Institute experience 1982-1992. Transfusion science, 1993, Volume: 14, Issue:3 Topics: Adult; Aged; Blood Component Removal; Child; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Co	1993
Cholesterol drugs: should you be taking one? Consumer reports, 1998, Volume: 63, Issue:10 Topics: Anticholesteremic Agents; Bile Acids and Salts; Cerebrovascular Disorders; Cholesterol; Coronary Dis	1998
What should I do for low HDL? Postgraduate medicine, 2000, Volume: 108, Issue:1 Topics: Adult; Aged; Cholesterol, HDL; Coronary Disease; Exercise; Humans; Male; Niacin; Risk Factors	2000
Evaluating niacin in its various forms. The American journal of cardiology, 2000, Dec-21, Volume: 86, Issue:12A Topics: Chemistry, Pharmaceutical; Cholesterol; Coronary Disease; Delayed-Action Preparations; Dietary Fats;	2000
Choice of lipid-regulating drugs. The Medical letter on drugs and therapeutics, 2001, May-28, Volume: 43, Issue:1105 Topics: Apolipoproteins; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Intera	2001
Niacin in patients with diabetes mellitus and coronary artery disease. The American journal of cardiology, 2001, May-01, Volume: 87, Issue:9 Topics: Coronary Disease; Diabetes Complications; Humans; Hypertriglyceridemia; Niacin	2001
Niacin after coronary bypass grafting and for coronary disease prevention. Circulation, 2001, Jul-10, Volume: 104, Issue:2 Topics: Cholesterol, HDL; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Artery Bypass; Cor	2001
Antioxidant supplements and simvastatin-niacin therapy. Arteriosclerosis, thrombosis, and vascular biology, 2001, Volume: 21, Issue:12 Topics: Antioxidants; Apolipoprotein A-I; Cholesterol, HDL; Coronary Disease; Drug Therapy, Combination; Hum	2001
Antioxidant versus lipid-altering therapy--some answers, more questions. The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22 Topics: Antioxidants; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Coronary Stenosis; Drug Therapy,	2001
Lipid-lowering drug use and cardiovascular events after myocardial infarction. The Annals of pharmacotherapy, 2002, Volume: 36, Issue:5 Topics: Cholesterol; Clofibrate; Cohort Studies; Coronary Artery Disease; Coronary Disease; Female; Humans;	2002
Marked benefit with sustained-release niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease. The American journal of cardiology, 1992, Apr-15, Volume: 69, Issue:12 Topics: Cholesterol, HDL; Coronary Disease; Delayed-Action Preparations; Humans; Hypertriglyceridemia; Male;	1992
Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis, 1992, Volume: 95, Issue:1 Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Humans; Hypercholesterole	1992
Unstable myocardial ischemia after the initiation of niacin therapy. The American journal of cardiology, 1991, Apr-15, Volume: 67, Issue:9 Topics: Aged; Angina Pectoris; Angina, Unstable; Cholesterol, HDL; Coronary Disease; Electrocardiography; Hu	1991
[Secondary prevention of ischemic heart disease]. Klinicheskaia meditsina, 1991, Volume: 69, Issue:1 Topics: Adult; Aged; Aspirin; Coronary Disease; Dipyridamole; Drug Therapy, Combination; Female; Hemodynamic	1991
[The effect of tocopherol and nicotinic acid on the microcirculation and blood coagulability in patients with ischemic heart disease]. Vrachebnoe delo, 1990, Issue:12 Topics: Adult; Aged; alpha-Tocopherol; Blood Coagulation; Conjunctiva; Coronary Disease; Drug Evaluation; Dr	1990
Effects of nicotinic acid and mepacrine on fatty acid accumulation and myocardial damage during ischemia and reperfusion. Journal of molecular and cellular cardiology, 1990, Volume: 22, Issue:2 Topics: Animals; Arrhythmias, Cardiac; Coronary Disease; Fatty Acids; Heart; Hemodynamics; Male; Myocardial	1990
Comparative effects of nicorandil, nitroglycerin, nicotinic acid, and SG-86 on the metabolic status and functional recovery of the ischemic-reperfused myocardium. Journal of cardiovascular pharmacology, 1987, Volume: 10 Suppl 8 Topics: Animals; Coronary Circulation; Coronary Disease; Dogs; Fatty Acids, Nonesterified; Female; Glucose;	1987
[Nicotinic acid in the treatment of chronic circulatory failure in patients with ischemic heart disease]. Vrachebnoe delo, 1989, Issue:9 Topics: Aged; Aged, 80 and over; Coronary Disease; Drug Evaluation; Female; Heart Failure; Hemodynamics; Hum	1989
Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. The American journal of cardiology, 1989, Oct-01, Volume: 64, Issue:12 Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Humans; Lipoproteins, HDL; Mal	1989
Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases. Cardiology, 1985, Volume: 72, Issue:5-6 Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clofibrate;	1985
Hypercholesterolemia: new values, new strategies. Hospital practice (Office ed.), 1986, Jan-30, Volume: 21, Issue:1A Topics: Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Colestipol; Coronary Disease; Energy Intake; Fe	1986
[Peculiarities of nicotinic acid formation in coronary heart disease with special reference to heart arrhythmias]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1988, Feb-01, Volume: 43, Issue:3 Topics: Angina Pectoris; Animals; Arrhythmias, Cardiac; Coronary Disease; Female; Humans; Kynurenine; Lipid	1988
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Archives of internal medicine, 1988, Volume: 148, Issue:1 Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Coronary Disease; Diet	1988
The pharmacology and therapeutics of lipid-lowering drugs. American pharmacy, 1987, Volume: NS27, Issue:11 Topics: Adult; Bile Acids and Salts; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitor	1987
Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia. The American journal of cardiology, 1987, Mar-01, Volume: 59, Issue:6 Topics: Child; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Homozygote; Human	1987
[Drug treatment of hyperlipidemia]. Therapeutische Umschau. Revue therapeutique, 1987, Volume: 44, Issue:8 Topics: Cholesterol; Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Factors;	1987
EPIDEMIOLOGIC APPROACH TO CHRONIC DISEASES. Archives of environmental health, 1964, Volume: 9 Topics: Chronic Disease; Coronary Disease; Dental Caries; Epidemiology; History; Humans; Lung Neoplasms; Neo	1964
Biological and disease patterns in South African inter-racial populations as modified by rise in privilege. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1972, Aug-12, Volume: 46, Issue:32 Topics: Adult; Aged; Blood Pressure; Body Weight; Cerebrovascular Disorders; Cholesterol; Coronary Disease;	1972

niacin and Coronary Disease